Compare FUSB & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUSB | TENX |
|---|---|---|
| Founded | 1952 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.4M | 81.1M |
| IPO Year | 1995 | 2001 |
| Metric | FUSB | TENX |
|---|---|---|
| Price | $17.10 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $10.29 |
| AVG Volume (30 Days) | 2.9K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.81 | $1.31 |
| 52 Week High | $16.99 | $19.40 |
| Indicator | FUSB | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 65.89 | 34.99 |
| Support Level | $15.75 | $1.34 |
| Resistance Level | N/A | $2.01 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 71.02 | 4.46 |
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.